FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average burden | | | | | | | | |
| haa aaaaaaaa | 0.5 | | | | | | | |

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | | | or | Secu | on 30(| (n) of the | Investmer | it Cor | npany Act | 01 1940 | | | | | | | | | |
|--|--|---|------------|--|---|--|------------|---|---|--------|--|---|---|---|--|----------------|-----------------------------------|---|-----|--|--|
| Name and Address of Reporting Person* Parikh Asit | | | | | 2. Issuer Name and Ticker or Trading Symbol Phathom Pharmaceuticals, Inc. [PHAT] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | |
| 1 drikii 7 tsit | | | | | \vdash | | | | | | | | - | X | Directo | r | | 10% Ow | ner | | |
| (Last) (First) (Middle) | | | | Date o /23/2 | | iest Trans | saction (M | onth/[| Day/Year) | | | Officer below) | (give title | | Other (spelow) | pecify | | | | | |
| C/O PHATHOM PHARMACEUTICALS, INC. | | | 4 1 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | | | | |
| 100 CAMPUS DRIVE, SUITE 102 | | | | 1 | | | | | | | | | Line) | | | | | | | | |
| | | | | | . | | | | | | | | | | X Form filed by One Reporting Person | | | | | | |
| (Street) FLORHAM | | | | Form filed by More than One R Person | | | | | | | | | | | | One Report | ting | | | | |
| PARK | N. | J | 07932 | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | | | |
| (City) | (S | tate) | (Zip) | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | to | | | | |
| | | Tab | le I - Non | -Deriv | ativ | e Se | curit | ies Ac | quired, | Dis | osed o | f, or Be | nefici | ally | Owned | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | | Execution Date, | | | Code (| Transaction Disposed Of Code (Instr. 5) | | ties Acquir d Of (D) (Ins | ies Acquired (A) or Of (D) (Instr. 3, 4 and | | 5. Amou Securitie Beneficia Owned F | s Fo | Form (D) or | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | Code | v | Amount | (A) o | (A) or (D) Price | | | oorted nsaction(s) str. 3 and 4) | | (| Instr. 4) | | | |
| Common Stock 05/23. | | | | 3/202 | 4 | | | A | | 10,500 |) ⁽¹⁾ A | \$ | 0 | 65,500 | | | D | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any C | | 4. Transaction Code (Instr. B) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | S | . Price of erivative ecurity nstr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4) | ly | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | | | | | | |
| | | | | | | | | | | | | | Amou | | | | | | | | |
| | | | | | Code | v | (A) | (D) | Date Exercisab | | xpiration ate | Title | Number of Shares | | | | | | | | |
| Stock Option (Right to Buy) | \$10.3 | 05/23/2024 | | | A | | | 17,500 | (2) | | 5/22/2034 | Common Stock | 17,50 | 0 | \$0 | 17,500 |) | D | | | |

Explanation of Responses:

1. The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

2. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

/s/ Molly Henderson, Attorney-05/24/2024 in-Fact for Asit Parikh

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.